Amgen Announces New Data At The American Heart Association Scientific Sessions 2026; New Late-Breaking Findings Show That Repatha Was A Highly Cost-Effective Treatment Option for High-Risk Patients Without A Prior Heart Attack Or Stroke

Amgen Announces New Data At The American Heart Association Scientific Sessions 2026; New Late-Breaking Findings Show That Repatha Was A Highly Cost-Effective Treatment Option for High-Risk Patients Without A Prior Heart Attack Or Stroke

UBS Maintains Buy on Walmart, Raises Price Target to $149

Nvidia Is Now Nearly 3 Times Cheaper Than Intel on Forward Earnings